1063 patents
Page 15 of 54
Utility
Multi-tumor Gene Signature for Suitability to Immuno-oncology Therapy
17 Nov 22
The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more genes of a pantumor inflammation gene panel.
Peter M. SZABO, Lan ZHANG, Keyur H. DESAI, Neeraj ADYA, Zhenhao QI, Kim ZERBA, Scott Adams ELY, Saumya PANT, George A. GREEN
Filed: 29 May 20
Utility
Methods of Treating Non-hodgkin Lymphoma Using 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
17 Nov 22
Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, in combination with tafasitamab, obinutuzumab, or tazemetostat, for treating, preventing or managing non-Hodgkin lymphoma.
Tonia J. Buchholz, Michael Pourdehnad, Poliana Alves Patah, Fan Wu
Filed: 20 Apr 22
Utility
System for Verifying Accuracy of Serially-connected Drug Modules In a Combinatorial Drug Delivery Device
17 Nov 22
In one aspect, a system is provided of verifying the accuracy of a plurality of serially-connected drug modules of a combinatorial drug delivery device, each of the drug modules including a drug reservoir, the system including: a machine-readable code located on each of the drug modules; application software configured to generate an activation code based on the machine-readable codes and the sequence of the machine-readable codes; a flow controller on the drug delivery device which is selectively actuatable to a use state to permit flow of drug from the drug delivery device; and, a control unit on the drug delivery device having a computing processing unit configured to compare the activation code with an authentication code, and, wherein, if the authentication code matches the activation code, the computing processing unit causes actuation of the flow controller to permit flow of the drug from the drug delivery device.
Martin John McLoughlin
Filed: 21 Oct 20
Utility
Combinatorial drug delivery device
15 Nov 22
In one aspect, a combinatorial drug delivery device is provided for delivering a predetermined selection of drug components.
Martin John McLoughlin, Chester Larrow, Mariano Mumpower
Filed: 10 May 19
Utility
Pharmaceutical compositions of albumin and rapamycin
15 Nov 22
The present invention provides compositions (such as pharmaceutical compositions), and commercial batches of such compositions, comprising nanoparticles comprising albumin and rapamycin.
Neil P. Desai
Filed: 28 Oct 20
Utility
2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases
15 Nov 22
Shun Su, Hannguang J. Chao, Adam James Clarke, R. Michael Lawrence
Filed: 16 Aug 18
Utility
5-MEMBERED and Bicyclic Heterocyclic Amides As Inhibitors of Rock
10 Nov 22
Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
Filed: 17 Jun 21
Utility
Methods of Treating Colorectal Cancer
10 Nov 22
This disclosure provides methods for treating a tumor derived from a colorectal cancer exhibiting a high degree of microsatellite instability in a subject comprising administering to the subject an anti-PD-1 antibody.
Michael AXELSON
Filed: 19 Apr 22
Utility
Amide-substituted Heterocyclic Compounds Useful As Modulators of IL-12, IL-23 And/or Ifn Alpha Responses
10 Nov 22
Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
Filed: 29 Apr 21
Utility
Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
8 Nov 22
Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium.
Hon-Wah Man, Mohit Atul Kothare
Filed: 9 Mar 21
Utility
Cyclic peptide immunomodulators
8 Nov 22
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Michael Matthew Miller, II, Martin Patrick Allen, Ling Li
Filed: 2 Oct 18
Utility
INTERLEUKIN-2/INTERLEUKIN-2 Receptor Alpha Fusion Proteins and Methods of Use
3 Nov 22
Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα.
Mary STRUTHERS, Jonathan Harry DAVIS, Michael Louis DOYLE, Priyanka Apurva MADIA
Filed: 13 May 22
Utility
Pet Imaging with PD-L1 Binding Polypeptides
3 Nov 22
Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
Paul E. MORIN, David DONNELLY, Dasa LIPOVSEK, Jochem GOKEMEIJER, Maria N. JURE-KUNKEL, David FABRIZIO, Martin C. WRIGHT, Douglas DISCHINO, Samuel J. BONACORSI, Jr., Ralph Adam SMITH, Virginie LAFONT, Daniel COHEN, David K. LEUNG
Filed: 4 Apr 22
Utility
Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
3 Nov 22
The disclosure provides LAG-3 antagonists and methods comprising the same for treating a cancer in a subject based on a LAG-3 density score and/or a LAG-3 proportion score in a tumor sample from the subject.
Cyrus HEDVAT, Robin EDWARDS, George C. LEE, Vipual Atulkumar BAXI
Filed: 22 Sep 20
Utility
Benzimidazole Inhibitors of Pad Enzymes
3 Nov 22
Khehyong Ngu
Filed: 7 Aug 19
Utility
6-AZAINDOLE Compounds
3 Nov 22
Alaric J. Dyckman, Dharmpal S. Dodd, Sreekantha Ratna Kumar, Durga Buchi Raju Barre, Srinivasan Kunchithapatham Duraisamy
Filed: 30 Jun 22
Utility
Macrocyclic toll-like receptor 7 (TLR7) agonists
1 Nov 22
Ashok V. Purandare, Honghe Wan, Liqi He, Sanjeev Gangwar, Shoshana L. Posy, Yam B. Poudel, Prasanna Sivaprakasam, Naidu S. Chowdari
Filed: 23 Apr 19
Utility
Composite Biomarker for Cancer Therapy
27 Oct 22
The disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antagonist, e.g., an anti-PD-1 or anti-PD-L1 antibody, in combination with an indoleamine 2,3-dioxygenase inhibitor, wherein the subject is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score.
Julia SANTUCCI PEREIRA DEL BUONO, David Martin NELSON, Enzo Yacobi KANDOUSSI, Bruce S. FISCHER, Megan M. WIND-ROTOLO, Yuko ISHII, Danielle Marie GREENAWALT
Filed: 24 Sep 20
Utility
4-AZAINDOLE Compounds
27 Oct 22
Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Brian K. Whiteley, John L. Gilmore, Sreekantha Ratna Kumar, Laxman Pasunoori, Pitani Veera Venkata Srinivas, Srinivasan Kunchithapatham Duraisamy, Subramanya Hegde, Rushith Kumar Anumula
Filed: 30 Apr 21
Utility
Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors
25 Oct 22
Saleem Ahmad
Filed: 26 Nov 19